Itraconazole Versus Amphotericin B for the treatment of Penicilliosis (IVAP)
| ISRCTN | ISRCTN97524945 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN97524945 |
| Secondary identifying numbers | 11CN |
- Submission date
- 10/10/2011
- Registration date
- 19/12/2011
- Last edited
- 23/01/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English Summary
Background and study aims
This is a study of adults (both male and female) with human immunodeficiency virus (HIV) infection who become infected with Penicillium marneffei, which causes a deadly infection known as penicilliosis . There are two drugs used to treat this infection in Viet Nam: amphotericin B and Itraconazole. Itraconazole is taken by mouth and is less expensive, while amphotericin B is taken through intravenous infusion, which is less convenient, causes more drug reactions, is more expensive and requires a higher level of care. Current WHO and Vietnamese guidelines recommend amphotericin B as the treatment of choice. Amphotericin B is not available in many resource-limited settings and doctors still use itraconazole to treat this disease. Experience in these settings shows that this treatment is effective. This study is designed to find out if itraconazole works as well as amphotericin B.
Who can participate?
Participants have to be HIV positive, be over 18 years old and suffer from penicilliosis (identified from blood, skin lesion scrapping, lymph node or bone marrow biopsy).
What does the study involve?
Participants will randomly be allocated to one of the two treatments: amphotericin B (0.7 mg/kg/day) through a vein in their arm or itraconazole by mouth (600 mg/day for 3 days, then 400 mg/day) for the first 2 weeks. Then everyone will be given itraconazole by mouth (400 mg/day) for the remaining 10 weeks of the treatment.
What are the possible benefits and risks of participating?
Participants will be treated according to regular clinical care when participating to the study. As we do not know if the drugs work in the same way, participants may not benefit directly from being in the study. The study results will help understanding how to best treat this fungal infection and it may help others with this disease in the future.
The risks associated with this study are the same as those which patients will experience in clinical care. Both drugs are routinely used in clinical care and study procedures will follow regular guidelines. A small amount of additional blood will be taken for laboratory tests which are not routine, but may improve diagnosis and understanding of the disease.
Where is the study run from?
There will be four study sites in Viet Nam: Hospital for Tropical Diseases in Ho Chi Minh City, Bach Mai Hospital, National Hospital for Tropical Diseases in Hanoi, Uong Bi Viet Nam Sweden Hospital in Quang Ninh Province and Viet Tiep Hospital in Hai Phong Province.
When is the study starting and how long is it expected to run for?
The study started in October 2012 and should last about four years.
Who is funding the study?
Funders of this trial are: The Department for International Development, the Wellcome Trust and the Medical Research Council in the UK.
Who is the main contact?
Dr Thuy Le
thuyl@oucru.org
Contact information
Dr Thuy Le
Scientific
Scientific
Centre for Tropical Medicine
Oxford University Clinical Research Unit (Viet nam)
764 Vo Van Kiet
Ward 1, District 5
Ho Chi Minh City
084
Viet Nam
Study information
| Study design | Randomized open-label comparative study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | A randomized, open-label, comparative study of the effectiveness of itraconazole versus amphotericin B in the induction treatment of penicilliosis in HIV-infected adults |
| Study acronym | IVAP |
| Study hypothesis | Itraconazole is at least as effective as amphotericin B for the acute-phase treatment of penicilliosis by conducting a randomized, open-label, comparative non-inferiority trial of the efficacy and safety of itraconazole versus amphotericin B. As of 15/02/2012, the following changes have been made on the trial record. Scientific title: Updated from A randomized, open-label, comparative study of the effectiveness of itraconazole versus amphotericin B in the induction treatment of penicilliosis in HIV-infected persons to A randomized, open-label, comparative study of the effectiveness of itraconazole versus amphotericin B in the induction treatment of penicilliosis in HIV-infected adults. Anticipated start date of trial was updated from 01/10/2010 to 01/05/2012. Anticipated end date of trial was updated from 31/12/2013 to 31/12/2015. As of 25/07/2013, the following changes have been made on the trial record: Anticipated start date of trial was updated from 01/05/2012 to 8/10/2012. Anticipated end date of trial was updated from 31/12/2015 to 31/3/2016. Other changes are indicated in the corresponding fields. |
| Ethics approval(s) | Oxford Tropical Research Ethics Committee, 03/12/2010, ref: 12-09 Hospital for Tropical Diseases' Committee of Scientific and Medical Ethics, 09/09/2010, ref: CS/ND/10/18 Added as of 15/02/2012: National Hospital for Tropical Diseasess Committee of Ethics in Biomedical Research, 12/12/2011, ref: 17/HDDD-NDTU Bach Mai Hospitals Committee of Ethics in Biomedical Research, 12/12/2011, ref: 39/HDDD Uong Bi Hospitals Committee of Science and Technology, 16/01/2012, ref: 49/HDKHKT-BV Viet Tiep Hospitals Committee of Science, 12/01/2012, ref: 01/BVVT/HDKH Added as of 25/07/2013: Vietnamese Ministry of Healths Evaluation Committee on Ethics in Biomedical Research, 12/09/2012, ref: 781/CN-BYT |
| Condition | Penicillium marneffei |
| Intervention | Current interventions as of 15/02/2012: This study is a randomized, open-label, comparative, multi-center trial designed to assess the efficacy and safety of itraconazole versus amphotericin B for the acute-phase treatment of penicilliosis in patients infected with HIV in Viet Nam. Patients will be randomized at 1:1 ration to the following treatment arms: Group 1: intravenous amphotericin B 0.7 mg/kg/day for 2 weeks Group 2: oral itraconazole 600 mg/day x first 3 days + 400 mg/day x 11 days After the 2-week acute phase therapy, all patients will continue on to the maintain-phase therapy with oral itraconazole 400 mg/day for 10 weeks, followed by the suppressive phase therapy with itraconazole 200 mg/day until CD4 count rises above 100 for 6 months on antiretroviral therapy for HIV. Randomization will be stratified by study site. Previous interventions This study is a randomized, open-label, comparative, multi-center trial designed to assess the efficacy and safety of itraconazole versus amphotericin B for the acute-phase treatment of penicilliosis in patients infected with HIV in Viet Nam. Patients will be randomized at 1:1 ration to the following treatment arms: Group 1: intravenous amphotericin B 0.6 mg/kg/day for 2 weeks Group 2: oral itraconazole 400 mg/day for 2 weeks After the 2-week acute phase therapy, all patients will continue on to the maintain-phase therapy with oral itraconazole 400 mg/day for 10 weeks, followed by the suppressive phase therapy with itraconazole 200 mg/day until CD4 count rises above 100 for 6 months on antiretroviral therapy for HIV. Randomization will be stratified for the following variables: 1. Study site 2. Presence of fungemia |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Amphotericin B, itraconazole |
| Primary outcome measure | Current primary outcome as of 15/02/2012: Absolute risk of death during the first 2 weeks after randomization Previous primary outcome: Mortality at 2 weeks of treatment (most deaths from penicilliosis occur in the acute phase of the disease and are reasonably assumed to have occurred by week 2 of presentation) |
| Secondary outcome measures | Current secondary outcomes as of 25/07/2013: 1.Clinical endpoints 1.1 Overall survival until week 24 1.2 Time to treatment success (defined by absence of fungal growth in follow up culture, temperature <38ºC for 3 days, and complete resolution of lesions or lesions in the final stage of healing as judged by treating clinicians) 1.3 Relapse-free survival until week 24 of therapy (i.e., time from treatment success to the first treatment relapse or death). (Relapse is defined as recurrence of culture-confirmed penicilliosis after achieving treatment success at week 12) 1.4 Deaths from penicilliosis until week 24 (causes of death will be determined by investigators) 1.5 Time to change of therapy from assigned study therapy 1.6 Total number of patients with Grade 3 and Grade 4 AEs and SAEs, and the cumulative incidence of Grade 3 and Grade 4 AEs and SAEs, associated with cessation of randomly assigned therapy between treatment arms 1.7 Antifungal medication adherence 1.8 Incidence of Immune Reconstitution Diseases 2. Microbiological endpoints 2.1 Time to blood culture sterilization 2.2 Rate of early fungicidal activity as determined by serial blood samplings during therapy and measured by the decrease in log colony forming units per mL of blood (CFUs/mL) 2.3 Frequency and patterns of itraconazole and amphotericin B resistance emergence 3. Pharmacological endpoints 3.1 Antifungal concentration time curves 3.2 Maximum antifungal concentrations/MIC, area under the curve (AUC) of antifungals/MIC over time Previous secondary outcomes (15/02/2012 to 25/07/2013): 1.Clinical endpoints 1.1 Overall survival until week 24 1.2 Time to treatment success (defined by absence of fungal growth in follow up culture, temperature <38ºC for 3 days, and complete resolution of lesions or lesions in the final stage of healing as judged by treating clinicians) 1.3 Relapse-free survival until week 24 of therapy (i.e., time from treatment success to the first treatment relapse or death). (Relapse is defined as recurrence of culture-confirmed penicilliosis after achieving treatment success at week 12) 1.4 Deaths from penicilliosis until week 24 (causes of death will be determined by investigators) 1.5 Time to change of therapy from assigned study therapy 1.6 Total number of patients with Grade 3 and Grade 4 AEs and SAEs, and the cumulative incidence of Grade 3 and Grade 4 AEs and SAEs, associated with cessation of randomly assigned therapy between treatment arms 1.7 Antifungal medication adherence 1.8 Incidence of Immune Reconstitution Diseases 2. Microbiological endpoints 2.1 Time to blood culture sterilization 2.2 Rate of early fungicidal activity as determined by serial blood samplings during therapy and measured by the decrease in log colony forming units per mL of blood (CFUs/mL) 2.3 Frequency and patterns of itraconazole and amphotericin B resistance emergence 3. Pharmacological endpoints 3.1 Antifungal concentration time curves 3.2 Maximum antifungal concentrations/MIC, area under the curve (AUC) of antifungals/MIC over time 4. Serological endpoints 4.1 Time to P. marneffei urinary antigen clearance 4.2 Rate of decrease in P. marneffei urinary antigen titers Original secondary outcomes (until 15/02/2012): 1. Clinical endpoints: 1.1. Overall survival until week 24 1.2. Time to treatment success (defined by absence of fungal growth in follow up culture, temperature <38ºC for 3 days, and complete resolution of lesions or lesions in the final stage of healing as judged by treating clinicians) 1.3. Relapse-free survival until week 24 of therapy (i.e. time from treatment success to the first treatment relapse or death). (Relapse is defined as recurrence of culture-confirmed penicilliosis after achieving treatment success at week 12) 1.4. Time to change in randomly assigned therapy 1.5. Total number of patients with Grade 3 and Grade 4 AEs and SAEs, and the cumulative incidence of Grade 3 and Grade 4 AEs and SAEs, associated with cessation of randomly assigned therapy between treatment arms 1.6. Antifungal medication adherence 2. Microbiological endpoints: 2.1. Time to blood culture sterilization 2.2. Rate of early fungicidal activity as determined by serial blood samplings during therapy and measured by the decrease in log colony forming units per mL of blood (CFUs/mL) 2.3. Frequency and patterns of itraconazole and amphotericin B resistance emergence by E-test 3. Pharmacological endpoints: 3.1. Antifungal concentration time curves in central (plasma) and PBM intracellular compartments 3.2. Maximum antifungal concentrations/MIC, area under the curve (AUC) of antifungals/MIC over time 4. Serological endpoints: 4.1. Time to P. marneffei urinary antigen clearance 4.2. Rate of decrease in P. marneffei urinary antigen titers |
| Overall study start date | 08/10/2012 |
| Overall study end date | 15/06/2016 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 440 |
| Participant inclusion criteria | Current inclusion criteria as of 15/02/2012 1. HIV positive AND 2. Age ≥18 years AND 3. Syndrome consistent with penicilliosis (primary or relapse) PLUS culture-confirmed diagnosis of penicilliosis (from blood, skin lesion scrapping, lymph node or bone marrow biopsy). Previous inclusion criteria 1. HIV positive 2. Age ≥ 15 years 3. Male and female participants 4. Syndrome consistent with penicilliosis (fever, malaise, hepatosplenomegaly, lymphadenopathy, typical skin lesions) plus culture confirmed diagnosis of penicilliosis (from blood, skin lesion scrapping/biopsy, lymph node or bone marrow biopsy) |
| Participant exclusion criteria | Current exclusion criteria as of 25/07/2013: 1. Age <18 2. Pregnancy or urine β-hCG positive 3. History of allergy or severe reaction to either itraconazole or amphotericin B 4. Central nervous system involvement (assessed clinically and by evidence of inflammation and/or infection in the CSF) 5. Use of the following prohibited drugs: phenytoin, barbiturates, carbamazepine, rifampin, HMG-CoA reductase inhibitors, cisapride, terfenadine, midazolam, dihydropyridine Ca channel blocker, cyclosporine, cyclophosphamide, tacrolimus, digoxin, quinidine, ergot derivatives, pimozide, coumadin, or investigational drugs. 6. Baseline AST or ALT ≥400 U/L 7. Absolute neutrophil count <500 cells/µL 8. Creatinine clearance of <30 by Cockcroft-Gault formula or on hemodialysis 9. Concurrent diagnosis of cryptococcal meningitis or active tuberculosis (as amphotericin B is the treatment of choice for cryptococcal meningitis, and tuberculosis treatment with INH and rifampin is contraindicated when used with itraconazole) 10. Current treatment with an antifungal drug for confirmed or suspected penicilliosis for >48 hours Previous exclusion criteria (15/02/2012 to 25/07/2013): 1. Age <18 2. Pregnancy or urine β-hCG positive 3. History of allergy or severe reaction to either itraconazole or amphotericin B 4. Central nervous system involvement (assessed clinically and by evidence of inflammation and/or infection in the CSF) 5. Use of the following prohibited drugs: phenytoin, barbiturates, carbamazepine, rifampin, isoniazid, H2 blocker, HMG-CoA reductase inhibitors, cisapride, terfenadine, midazolam, dihydropyridine Ca channel blocker, cyclosporine, cyclophosphamide, tacrolimus, digoxin, quinidine, ergot derivatives, pimozide, coumadin, or investigational drugs. 6. Baseline AST or ALT ≥10 times the upper limit of normal 7. Absolute neutrophil count < 500 cells/µL 8. Creatinine clearance of <10 by Cockcroft-Gault formula or on hemodialysis 9. Concurrent diagnosis of cryptococcal meningitis or active tuberculosis (as amphotericin B is the treatment of choice for cryptococcal meningitis, and tuberculosis treatment with INH and Rifampin is contraindicated when used with itraconazole) 10. Current treatment with an antifungal drug for confirmed or suspected penicilliosis for >48 hours Original exclusion criteria (until 15/02/2012): 1. Age < 15 2. Pregnancy or urine β-hCG positive 3. History of allergy or severe reaction to either itraconazole or amphotericin B 4. Unable to take oral medications 5. Documented treatment failure due to suspected drug resistance to either itraconazole or amphotericin B from another hospital or an outpatient clinic 6. Use of the following prohibited drugs: phenytoin, barbiturates, carbamazepine, rifampin, isoniazid, H2 blocker, HMG-CoA reductase inhibitors, cisapride, terfenadine, midazolam, dihydropyridine calcium channel blocker, cyclosporine, cyclophosphamide, tacrolimus, digoxin, coumadin, or investigational drugs. 7. Baseline aspartate transaminase (AST) or alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal 8. Creatinine clearance of < 10 by Cockcroft-Gault formula or on hemodialysis 9. Concurrent diagnosis of cryptococcal meningitis or active tuberculosis (as amphotericin B is the treatment of choice for cryptococcal meningitis, and tuberculosis treatment with Isoniazid (INH) and Rifampin is contraindicated when used with itraconazole) |
| Recruitment start date | 08/10/2012 |
| Recruitment end date | 18/12/2015 |
Locations
Countries of recruitment
- Viet Nam
Study participating centre
Centre for Tropical Medicine
Ho Chi Minh City
084
Viet Nam
084
Viet Nam
Sponsor information
University of Oxford (UK)
University/education
University/education
c/o Ms Heather House
Head of Clinical Trials and Research Governance
Joint Research Office
Block 60
Churchill Hospital
Old Road
Headington
Oxford
OX3 7LJ
England
United Kingdom
| Website | http://www.ox.ac.uk/ |
|---|---|
"ROR" |
https://ror.org/052gg0110 |
Funders
Funder type
Government
Current sources of funding as of 15/02/2012:
No information available
Joint Global Health Trials Initiative (WT-MRC-DFID) ref:100033
No information available
Department for International Development (UK)
No information available
The Wellcome Trust (UK)
No information available
Medical Research Council (UK)
Government organisation / National government
Government organisation / National government
- Alternative name(s)
- Medical Research Council (United Kingdom), UK Medical Research Council, MRC
- Location
- United Kingdom
Previous sources of funding:
No information available
Department for International Development (UK)
No information available
The Wellcome Trust (UK) ref:100033
No information available
Medical Research Council (UK) ref: G1100682
Government organisation / National government
Government organisation / National government
- Alternative name(s)
- Medical Research Council (United Kingdom), UK Medical Research Council, MRC
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 15/06/2017 | 23/01/2019 | Yes | No |
Editorial Notes
23/01/2019: Publication reference added
27/01/2016: The overall trial end date has been updated from 31/03/2016 to 15/06/2016 and the recruitment end date has been updated from 31/03/2016 to 18/12/2015.
